InvestorsHub Logo
icon url

LessIsMore

05/01/20 6:03 PM

#280994 RE: biosectinvestor #280993

With a 15 times multiple

15X sales, that's interesting.

For the sake of sanity it should be noted that Dendreon was sold for $495 Million or less than 1.5X sales.
icon url

sukus

05/01/20 6:14 PM

#280999 RE: biosectinvestor #280993

With say $150k per patient, that would translate about 2500 patients. I heard annual capacity able to serve 5000 patients. That means double that mcap?

Without the side effects, I would foresee demand supply issues. Better supply is ready to meet demand.

Is that why we have to wait this long to also make sure supply is ready besides waiting for data to mature?
icon url

antihama

05/01/20 9:52 PM

#281021 RE: biosectinvestor #280993

The book was written for Dendreon; chapters include various clinical trials, approval, near bankruptcy, being bought out by several companies, and current sales. It's parent now is a Chinese conglomerate. Can't wait to get to the next chapter of NWBO's DCVAX saga about TLD, hopefully in a month or 2.